Accès ouvert
2026
article
OpenAlex
H. Ludwig, Thomas Melchardt, E. Terpos, J. Bila et autres
Background. In very elderly pts with NDMM data on the efficacy of Isatuximab-lenalidomide-dexamethasone (Isa-Rd) induction therapy followed by Isa-R maintenance therapy compared to Rd induction followed by R maintenance are not available so far.Aim. In this prospective, randomized study, we aimed to …
at, gr, rs, es, sk
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
S. P. Gampenrieder, Gabriel Rinnerthaler, A. Pichler, Walter Herz et autres
Abstract Background: Elacestrant is the first oral Selective Estrogen Receptor Degrader (SERD) to be approved in the EU as of September 2023. Since its approval, testing for mutations in the estrogen receptor 1 (ESR1) gene has become standard care for patients with …
at
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Gabriel Rinnerthaler, S. P. Gampenrieder, A. Pichler, Walter Herz et autres
Abstract Background: Based upon the CLEOPATRA trial, a combination of docetaxel plus trastuzumab and pertuzumab (THP) has been the standard treatment for patients with metastatic HER2-positive breast cancer. However, this standard has recently been challenged by the results of the DESTINY-Breast09 study, …
at
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Vanessa Castagnaviz, S. P. Gampenrieder, A. Pichler, Walter Herz et autres
Abstract Background: Second primary tumors (SPTs) occur in approximately 10% of patients following an initial cancer diagnosis and are associated with increased cancer-related mortality. Ongoing advancements in systemic therapies have led to a growing population of both breast cancer (BC) survivors and …
at
(code pays fourni par la source)